Form 4: Hologic Officer Reports Equity Transactions

Hologic's Principal Accounting Officer, Benjamin Jordan Cohn, reported recent acquisitions of restricted stock units and dispositions for tax obligations.

Summary

• Benjamin Jordan Cohn, Principal Accounting Officer of Hologic Inc. (HOLX), reported several transactions involving common stock.
• On November 7, 2025, 1,078 shares of common stock were withheld for tax obligations at a price of $74.1 per share, related to the settlement of performance/restricted stock units.
• On November 10, 2025, Mr. Cohn acquired 5,047 restricted stock units (RSUs). These RSUs will vest in equal installments on each of the first three anniversaries of the grant date, November 10, 2025, and are settled on a one-for-one basis in common stock.
• On November 11, 2025, an additional 181 shares of common stock were withheld for tax obligations at a price of $74.6 per share, also connected to RSU/PSU settlement.
• Following these transactions, Mr. Cohn beneficially owns 18,071 shares of Hologic Inc. common stock directly.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions related to executive compensation, including RSU grants and tax withholdings, which are standard and do not indicate a significant positive or negative shift in company outlook.

Positives

• Acquisition of 5,047 restricted stock units on November 10, 2025, aligning management interests with shareholder value through future equity vesting.

Negatives

• No inherently negative events were reported; the dispositions were for tax obligations related to the vesting of equity awards, which is a standard practice.

Future Outlook

The 5,047 restricted stock units granted on November 10, 2025, are scheduled to vest in equal installments on each of the first three anniversaries of the grant date.

Industry Context

Form 4 filings are standard disclosures for insider transactions, reflecting routine executive compensation practices involving equity awards and associated tax withholdings. This is a common mechanism for aligning executive incentives with company performance.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) as a component of executive compensation, with shares withheld for tax purposes upon vesting, is a widely adopted practice across various industries, including the medical technology sector where Hologic operates. This aligns with typical compensation structures designed to incentivize long-term performance and retention.

Stakeholder Impact

• Shareholders: The grant of restricted stock units aligns the Principal Accounting Officer's interests with long-term shareholder value.
• Employees: Reflects standard executive compensation practices within the company.

Next Steps

• Future vesting of the 5,047 restricted stock units in equal installments on the first three anniversaries of November 10, 2025.

Key Dates

Keywords

Hologic, HOLX, Form 4, Insider Transaction, Restricted Stock Units, Equity Compensation, Beneficial Ownership